Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.51 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.51 |
| ▸ | NCF1 | P14598 | 2/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24943586 | 0.88 | NCF1 (0.52) | NCF1CYP1A2CYSLTR2CYSLTR1NOS2 | |
| SCHEMBL21066763 | 0.85 | NCF1 (0.46) | NCF1CYP1A2CYSLTR2CYSLTR1PDE10A | |
| SCHEMBL4729159 | 0.83 | CXCR4 (0.49) | NCF1CXCR4CYP1A2CYSLTR2CYSLTR1 | |
| SCHEMBL21066731 | 0.82 | GPBAR1 (0.48) | NCF1CYP1A2CYSLTR2CYSLTR1PDE10A | |
| SCHEMBL12468389 | 0.80 | NCF1 (0.52) | NCF1CYP1A2CYSLTR2CYSLTR1PDE10A | |
| SCHEMBL19603244 | 0.78 | NCF1 (0.40) | NCF1CYP1A2CYSLTR2CYSLTR1PDE10A | |
| SCHEMBL15212024 | 0.76 | HDAC1 (0.56) | NCF1CXCR4CYP1A2CYSLTR2CYSLTR1 | |
| SCHEMBL9736388 | 0.75 | CYSLTR1 (0.48) | CYSLTR2CYSLTR1PDE10AALOX5 | |
| SCHEMBL3892348 | 0.74 | HDAC1 (0.51) | NCF1CXCR4CYP1A2CYSLTR2CYSLTR1 | |
| SCHEMBL2305245 | 0.74 | PDE10A (0.50) | NCF1CYP1A2CYSLTR2CYSLTR1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | CHU DANIEL (US) | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | MRPL21, CYP51A1, CEL | CARM1 4584/4885PRMT6 3551/4885PRMT8 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.